
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>




































This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 19.6 kDa. The protein migrates as 27-43 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to different glycosylation.
>85% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:

Human PTH1R, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 85% (With Star Ribbon Pre-stained Protein Marker).

Immobilized Human PTH1R, His Tag (Cat. No. PTR-H5222) at 5 μg/mL (100 μL/well) can bind PTH1R Recombinant Rabbit Monoclonal Antibody with a linear range of 0.01-0.313 ng/mL (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant Human Parathyroid Hormone (1-34), Shanghai Fosunpharma | Approved | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Details | |||||||
| Recombinant parathyroid hormone biosimilar(Chongqing Fujin Biological Medicine) | Approved | Chongqing Fujin Biological Medicine Co Ltd | Details | |||||||
| Teriparatide biosimilar (CinnaGen) | rhPTH (1-34) (CinnaGen) | Approved | Cinnagen | CinnoPar | Iran | Osteoporosis | Cinnagen | 2013-01-01 | Osteoporosis | Details |
| Teriparatide biosimilar (Zydus Cadila) | rhPTH (1-34) (Zydus Cadila) | Approved | Zydus Cadila | India | Osteoporosis | Zydus Cadila | 2014-01-01 | Osteoporosis | Details | |
| Teriparatide biosimilar (Virchow/Sun) | rhPTH (1-34) (Virchow/Sun) | Approved | Sun Pharmaceutical Industries Ltd, Virchow Group | Bonista, Osteotide | Osteoporosis | Details | ||||
| Teriparatide biosimilar (Shanghai United Cell ) | Approved | Shanghai United Cell Biotechnology Co Ltd | Mainland China | Osteoporosis | Shanghai United Cell Biotechnology Co Ltd | 2017-03-22 | Osteoporosis | Details | ||
| Teriparatide biosimilar (STADA Arzneimittel AG) | rhPTH (1-34) (STADA Arzneimittel AG) | Approved | Stada Arzneimittel Ag | Movymia | EU | Osteoporosis | Stada Arzneimittel Ag | 2017-01-11 | Osteoporosis | Details |
| Teriparatide biosimilar (Biosidus) | rhPTH (1-34) (Biosidus) | Approved | Biosidus | Osteofortil | Ecuador | Osteoporosis | Biosidus | 2012-08-01 | Osteoporosis | Details |
| Teriparatide biosimilar (Amega Biotech) | rhPTH (1-34) (Amega Biotech) | Approved | Amega Biotech | Osteoporosis | Details | |||||
| Teriparatide biosimilar (Theramex) | Approved | Theramex Ireland Ltd | Livogiva | EU | Osteoporosis | Theramex Ireland Ltd | 2020-08-27 | Osteoporosis | Details | |
| Teriparatide acetate | hPTH (1-34) acet. H2O; AK-159; MN-10-T | Approved | Union Square Ventures Llc | Parathar, Teribone | Japan | Hypocalcemia; Osteoporosis | null | 1987-03-31 | Osteoporosis; Hypocalcemia | Details |
| Teriparatide biosimilar (Intas Pharmaceuticals) | rhPTH (1-34) (Intas Pharmaceuticals); INTG8; INTG-8 | Approved | Intas Biopharmaceuticals | Terifrac | EU | Osteoporosis | null | 2010-12-01 | Osteoporosis | Details |
| Teriparatide biosimilar (USV) | Approved | Usv Ltd | Osteoporosis | Details | ||||||
| Teriparatide biosimilar (Gedeon Richter) | rhPTH (1-34) (Gedeon Richter) | Approved | Gedeon Richter Plc | Terrosa | Japan | Osteoporosis | Mochida Pharmaceutical Co Ltd | 2017-01-04 | Osteoporosis; Fractures, Stress | Details |
| Teriparatide biosimilar (Salubris) | G56-W1; SAL-001 | Approved | Shenzhen Salubris Pharmaceuticals Co Ltd | 欣复泰 | Mainland China | Osteoporosis, Postmenopausal | Suzhou Genemen Biotech Co Ltd | 2019-09-29 | Osteoporosis, Postmenopausal | Details |
| Teriparatide | MN-10T; LY 333334; hPTH-1-34; EB-613 | Approved | Eli Lilly And Company | Forteo, Forsteo, 复泰奥 | Mainland China | Osteoporosis; Osteoporosis, Postmenopausal | Eli Lilly Nederland BV | 2002-11-26 | Colles' Fracture; Anorexia Nervosa; Chronic Kidney Disease-Mineral and Bone Disorder; Hypoparathyroidism; Periodontitis; Fractures, Bone; Osteoarthritis, Knee; Spinal Fractures; Back Pain; Humeral Fractures; Femoral Neck Fractures; Alveolar Bone Loss; Hypocalcemia; Osteoporosis, Postmenopausal; Spinal Cord Injuries; Bone Diseases, Metabolic; Menopausal symptoms; Osteoporosis; Cartilage Diseases; Hyperparathyroidism, Secondary; Drug-Related Side Effects and Adverse Reactions | Details |
| Parathyroid hormone (Shire) | NPSP-795; rhPTH (1-84); rhPTH-1-84; PTH (1-84); SB-423562; PTH 1-84; NPSP-558; SHP-635; SHP-634; ALX-111; 423562; EBP-05; EB-612 | Approved | Shire | Natpara, Preotact, Natpar | EU | Hypoparathyroidism | Takeda Pharmaceuticals International AG Ireland Branch | 2006-04-24 | Osteoporosis; Bone Diseases, Endocrine; Osteoporosis, Postmenopausal; Hypocalcemia; Psoriasis; Hypoparathyroidism; Hyperparathyroidism | Details |
| Teriparatide biosimilar (Pfenex) | rhPTH (1-34) (Pfenex); PF-708 | Approved | Pfenex | Bonsity, Qutavina | United States | Osteoporosis | Alvogen | 2019-10-04 | Osteoporosis | Details |
| Abaloparatide | BA-058; ITM-058; BIM-44058; BA-058-SC; BA-058-TD | Approved | Ipsen | Tymlos | Japan | Osteoporosis, Postmenopausal | Teijin Pharma | 2017-04-28 | Osteoporotic Fractures; Osteoporosis; Osteoporosis, Postmenopausal; Intervertebral Disc Degeneration; Fractures, Bone | Details |
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Teriparatide transdermal (Corium International) | Phase 2 Clinical | Corium International Inc | Osteoporosis | Details | |
| Recombinant Human Parathyroid Hormone (1-34)(Shanghai Celgen Biopharmaceuticals) | Phase 2 Clinical | Shanghai Celgen Bio-Pharmaceutical Co Ltd | Osteoporosis | Details | |
| Hemoparatide | hPTH-137 | Phase 1 Clinical | Pharis Biotec | Psoriasis | Details |
| KUR-111 | I-0401; KUR-111 | Phase 2 Clinical | Kuros Biosciences | Fractures, Bone | Details |
| Teriparatide biosimilar (Stelis) | SBL-001 | Phase 1 Clinical | Stelis Biopharma | Osteoporosis | Details |
| Teriparatide biosimilar (Shanghai CAS Shenglongda Biotech) | Phase 3 Clinical | Shanghai Zhongke Shenglongda Biotechnology (Group) Co Ltd | Osteoporosis, Postmenopausal | Details | |
| Teriparatide biosimilar (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical) | Phase 1 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Osteoporosis | Details | |
| Parathyroid hormone 1-84(Sichuan Luzhou Buchang Biopharmaceutical) | Phase 1 Clinical | Sichuan Luzhou Buchang Biopharmaceutical Co Ltd | Hypocalcemia | Details | |
| BMD-1221 | BMD-1221 | Clinical | University Of Arkansas System | Fractures, Bone | Details |
| Teriparatide biosimilar(Hybio Pharmaceutical) | Phase 1 Clinical | Hybio Pharmaceutical Co Ltd | Osteoporosis, Postmenopausal | Details | |
| MT-1013 | MT-1013 | Phase 1 Clinical | Shaanxi Micot Technology Co Ltd | Hyperparathyroidism, Secondary | Details |
| Parathyroid hormone 1-84 (Kerun Biopharmaceutical) | Phase 3 Clinical | Chongqing Kerun Biologic Pharmaceutical Development Co Ltd | Osteoporosis, Postmenopausal | Details | |
| PCO-371 | PCO-371 | Chugai Pharmaceutical Co Ltd | Details | ||
| KUR-113 | KUR-113; I-040202; Fibrin-PTH | Phase 2 Clinical | Kuros Biosciences | Spinal Diseases; Intervertebral Disc Degeneration; Wounds and Injuries | Details |
| T3-sulfate (Bracco SpA) | Phase 2 Clinical | Bracco Spa | Hypothyroidism | Details | |
| Teriparatide biosimilar (National Institute of Dental and Craniofacial Research) | rhPTH (1-34) (National Institute of Dental and Craniofacial Research) | Phase 3 Clinical | National Institute Of Dental And Craniofacial Research | DiGeorge Syndrome; Hypothyroidism; Hypoparathyroidism | Details |
| AZP-3601 | AZP-3601 | Phase 2 Clinical | Harvard Medical School, Massachusetts General Hospital | Hypoparathyroidism | Details |
| TransCon PTH | ACP-014 | Phase 3 Clinical | Ascendis Pharma | Endocrine System Diseases; Parathyroid Diseases; Hypoparathyroidism | Details |
| MBX-2109 | MBX-2109 | Phase 1 Clinical | MBX Biosciences Inc | Details | |
| RT-102(Rani) | RT-102 | Phase 1 Clinical | Rani Therapeutics Holdings Inc | Osteoporosis | Details |
| Teriparatide transdermal (Zosano Pharma) | B-106; B-104; ZP-PTH; ThPTH (1-34); TH-0229 | Phase 2 Clinical | Zosano Pharma Corp | Osteoporosis; Osteoporosis, Postmenopausal | Details |
This web search service is supported by Google Inc.




